NCT05922878ClinicalTrials.gov
Study of ALTO-300 in MDD
A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder
בקצרה
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
שלב 2דרושים 325 משתתפים75 אתריםמדינה אחת
קטגוריות
רשום במרשם אחד
- ClinicalTrials.govNCT05922878פתיחת רשומה זו ב־ClinicalTrials.govסונכרן לפני 3 שבועות
מחקר יחיד יכול להיות רשום בכמה מרשמים. אנו מציגים אותו פעם אחת ומקשרים לכל רשומה שברשותנו.
מידע הניסוי מוצג כפי שפורסם על ידי המרשם, בשפת המקור שלו.
מתעניינים במחקר הזה?
התחברות או צרו חשבון כדי לרשום את התעניינותכם ולעקוב אחר המחקר הזה.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study: 325 participants (target), run at 75 sites.
How this score is built
- Enrolment24/40
321 participants (target)
- Site count19/25
45 sites
- Country count0/15
Single country
- Planned duration8/10
Planned over about 42 months
- Sponsor scale2/10
Alto Neuroscience has led 5 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
תקציר
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
מצבים רפואיים
- Major Depressive Disorder
זכאות
| מין | הכול |
|---|---|
| גילאים | 18 Years – 70 Years |
| מתנדבים בריאים | לא |
זכאות כפי שנכתבה במרשם
זכאות במשפטים פשוטים
הקריטריונים של רשומה זו טרם פורקו למשפטים נפרדים. טקסט המרשם שלמעלה שלם והוא הגרסה המחייבת.
תכנון המחקר
| סוג המחקר | התערבותי |
|---|---|
| שלב | שלב 2 |
| הקצאה | אקראי |
| מודל ההתערבות | PARALLEL |
| מטרה ראשית | TREATMENT |
| הסתרה | QUADRUPLE (4) |
| גיוס | דרושים 325 משתתפים |
נותן חסות ושותפים
- Alto Neuroscience נותן חסות
זרועות והתערבויות
- ALTO-300EXPERIMENTAL
Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).
- PlaceboPLACEBO_COMPARATOR
Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.
התערבויות
- תרופה ALTO-300
ALTO-300 capsule QD
- תרופה Placebo
Placebo capsule QD
מדדי תוצאה
מדד תוצאה ראשוני
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS).
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
מסגרת זמן Change over time for up to week 6
מדד תוצאה משני
To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Åsberg Depression Rating Scale (MADRS)
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
מסגרת זמן Change over time for up to week 6
מדד תוצאה משני
To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
מסגרת זמן Change over time for up to week 6
מדד תוצאה משני
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.
Incidence, severity, and relatedness of Adverse Events
מסגרת זמן Assessed from Day 1 to Week 14
מדד תוצאה משני
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.
Assessment of Heart Rate
מסגרת זמן Assessed from Day 1 to Week 14
מדד תוצאה משני
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.
Assessment of Weight Change
מסגרת זמן Assessed from Day 1 to Week 14
מדד תוצאה משני
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.
Assessment of Blood Pressure
מסגרת זמן Assessed from Day 1 to Week 14
מדד תוצאה משני
To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).
The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.
מסגרת זמן Assessed from Day 1 to Week 15
תאריכים
| תאריך התחלה | 8 ביוני 2023 (בפועל) |
|---|---|
| סיום ראשוני | 1 בדצמבר 2026 (משוער) |
| סיום | 1 בדצמבר 2026 (משוער) |
| פורסם לראשונה | 28 ביוני 2023 (בפועל) |
| עודכן לאחרונה | 26 באוקטובר 2026 |
| התוצאות פורסמו | לא צוין ברשומת המרשם |
| המצב אומת לאחרונה | אוקטובר 2026 |
בפועל פירושו שהאירוע התרחש. משוער פירושו שנותן החסות צופה אותו. שתי המשמעויות שונות זו מזו.
מיקומים
30 אתרים מגייסים
United States
| מתקן | עיר | מדינה או אזור | מצב |
|---|---|---|---|
| Site 114 | Albuquerque | New Mexico | מגייס |
| Site 216 | Allentown | Pennsylvania | הופסק |
| Site 316 | Austin | Texas | מגייס |
| Site 218 | Bellflower | California | מגייס |
| Site 317 | Blackfoot | Idaho | בוטל |
| Site 236 | Boise | Idaho | מגייס |
| Site 119 | Boise | Idaho | פעיל, ללא גיוס |
| Site 318 | Carlsbad | California | פעיל, ללא גיוס |
| Site 310 | Chicago | Illinois | פעיל, ללא גיוס |
| Site 202 | Cincinnati | Ohio | מגייס |
| Site 159 | Clermont | Florida | הופסק |
| Site 207 | Clinton | Utah | פעיל, ללא גיוס |
| Site 203 | Colorado Springs | Colorado | פעיל, ללא גיוס |
| Site 239 | Conroe | Texas | מגייס |
| Site 229 | Creve Couer | Missouri | בוטל |
| Site 102 | Dallas | Texas | פעיל, ללא גיוס |
| Site 343 | Denver | Colorado | מגייס |
| Site 349 | Evergreen | Colorado | פעיל, ללא גיוס |
| Site 345 | Evergreen | Colorado | פעיל, ללא גיוס |
| Site 277 | Fairfax | Virginia | מגייס |
| Site 238 | Fayetteville | Georgia | מגייס |
| Site 148 | Fort Worth | Texas | בוטל |
| Site 347 | Fort Worth | Texas | הופסק |
| Site 217 | Glendale | California | פעיל, ללא גיוס |
| Site 279 | Hattiesburg | Mississippi | בוטל |
| Site 199 | Hickory | North Carolina | פעיל, ללא גיוס |
| Site 320 | Houston | Texas | מגייס |
| Site 275 | Houston | Texas | מגייס |
| Site 215 | Jackson | Mississippi | פעיל, ללא גיוס |
| Site 335 | Lafayette | California | מגייס |
| Site 335 | Lafayette | California | מגייס |
| Site 344 | Las Vegas | Nevada | מגייס |
| Site 209 | Los Angeles | California | פעיל, ללא גיוס |
| Site 240 | Mankato | Minnesota | מגייס |
| Site 201 | Marrero | Louisiana | הופסק |
| Site 219 | Mather | California | מגייס |
| Site 350 | Media | Pennsylvania | בוטל |
| Site 225 | Miami Gardens | Florida | פעיל, ללא גיוס |
| Site 190 | Miami Lakes | Florida | פעיל, ללא גיוס |
| Site 265 | Minneapolis | Minnesota | מגייס |
| Site 194 | Mission Viejo | California | הופסק |
| Site 206 | Missouri City | Texas | בוטל |
| Site 198 | Monroe | Louisiana | הופסק |
| Site 267 | Moorpark | California | מגייס |
| Site 352 | Moosic | Pennsylvania | פעיל, ללא גיוס |
| Site 283 | New York | New York | מגייס |
| Site 319 | New York | New York | פעיל, ללא גיוס |
| Site 214 | Norwalk | Connecticut | בוטל |
| Site 161 | Okeechobee | Florida | פעיל, ללא גיוס |
| Site 195 | Oklahoma City | Oklahoma | הופסק |
25 אתרים נוספים מצוינים ברשומת המרשם.
מסמכי המחקר
לא צורפו מסמכים ברשומת מרשם זו.
שינויים לאורך זמן
- 26 באוקטובר 2026
יעד הגיוס השתנה
Enrollment target revised up from 321 to 325
321325
- 26 באוקטובר 2026
אתר נוסף
30 sites added (75 total)
4575